Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Novartis
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Memorial Sloan Kettering Cancer Center
Hoffmann-La Roche
Beijing Tiantan Hospital
Columbia University
Eisai Inc.
Massachusetts Eye and Ear Infirmary
Olivia Newton-John Cancer Research Institute
Assistance Publique - Hôpitaux de Paris
Hoffmann-La Roche
Corcept Therapeutics
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center